Severity
Moderate
FDA Drug recall · Reported July 26, 2017
Lack of Assurance of Sterility; media fill failure at manufacturer
PharMedium Services, Llc recalled Potassium PHOSphate in 0.9% Sodium Chloride Injection, 7.5 mMol in 100 mL in 150 mL Intra… - a moderate-severity action.
Potassium PHOSphate in 0.9% Sodium Chloride Injection, 7.5 mMol in 100 mL in 150 mL Intra… was recalled by PharMedium Services, Llc in July 26, 2017. Reason: Lack of Assurance of Sterility; media fill failure at manufacturer. Check the official notice for the remedy. Verify recall #D-0992-2017 with the FDA Drug before acting.
The recall
PharMedium Services, Llc issued this moderate-severity FDA Drug recall-Lack of Assurance of Sterility; media fill failure at manufacturer.
Sourced from official FDA Drug enforcement records. Verify recall #D-0992-2017 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0992-2017) was formally reported on July 26, 2017, with the manufacturer initiating the action on June 26, 2017. It is classified under Moderate severity (Class II), with a current status of Terminated. PharMedium Services, Llc is listed as the recalling firm, operating out of Sugar Land, TX. Federal records list the affected scope as N/A.
The documented reason for this recall is: Lack of Assurance of Sterility; media fill failure at manufacturer Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
N/A
Related Recalls
6
5 from same agency
Potassium PHOSphate in 0.9% Sodium Chloride Injection, 7.5 mMol in 100 mL in 150 mL Intravia Bag, Rx Only, PharMEDium Services, LLC 12620 W. Airport Blvd #130 Sugar Land, TX 77478 800-523-7749 Service Code 2K5298 NDC# 61553-298-48NDC# 61553-298-48
Lack of Assurance of Sterility; media fill failure at manufacturer
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0992-2017 |
| Date reported | July 26, 2017 |
| Date initiated | June 26, 2017 |
| Recalling firm | PharMedium Services, Llc |
| Firm location | Sugar Land, TX |
| Affected scope | N/A |
| Distribution | Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported July 26, 2017. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.